This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Identifying and Addressing Unmet Therapeutic Needs in MS

Clyde E. Markowitz, MD

Published: March 25, 2015

Article Abstract

Current disease-modifying treatments in multiple sclerosis (MS) are partially effective in reducing relapses and slowing disease progression, but these treatments do not restore function and are effective mainly in relapsing forms of MS. Unmet needs in MS include treatments for progressive forms of MS, agents with improved efficacy and safety profiles and that comprehensively manage MS symptoms, and medications with neuroprotective or remyelinating properties. Some adverse effects of disease-modifying agents could be reduced if medications are developed with more specific treatment targets, and research into the pathogenesis of MS may lead to agents that could restore myelin or protect nerves from inflammation.

From the Department of Neurology and the Multiple Sclerosis Center, the Hospital of the University of Pennsylvania, Philadelphia.

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Related Articles

Volume: 76

Quick Links: